INTRODUCTION AND OBJECTIVES: Bioelectronic technologies that are capable of modulating activity of the peripheral nervous system offer powerful options in targeted treatment of organ dysfunction and pain, with features that have the potential to bypass limitations of traditional pharmacological approaches. Here we introduce a miniaturized, fully implantable wireless bio-optoelectronic system that circumvents these challenges by monitoring and modulating bladder function in an active, closed-loop fashion through optogenetic, as opposed to electrical, modulation of bladder-projecting sensory afferents.
METHODS: The resulting technology includes a wireless strain gauge that wraps around the bladder, enabling measurement of changes bladder size, and includes integrated microscale light emitting diodes (µLEDs) to allow optogenetic modulation. This approach avoids the use of potentially damaging nerve-interfacing electrodes or implantation of invasive bladder catheters, which can disrupt normal bladder function. The strain gauge and mLEDs operate via an implanted Bluetooth base station that allows for wireless monitoring of bladder activity and enables closed-loop control via optogenetics. Utilizing herpes simplex viral (HSV) vectors to deliver the lightactivated proton pump, archaerhodopsin (Arch, which can inhibit neuronal firing) to bladder afferents.
RESULTS: We can chronically measure bladder activity using the implanted strain gauge and these measurements correlate with traditional bladder pressure cystometry, void volumes and overall bladder size. Using the wireless optoelectronic strain gauge, we can clearly identify the onset of altered voiding behaviors associated with bladder inflammation, and activation of Arch in bladder afferents can reduce the number of void associated with inflammation. We programed our software to recognize these changes in bladder frequency associated with bladder inflammation and to activate the µLEDs. Closed loop activation of µLEDs reduced voiding frequency in the Arch-injected animal compared to eYFP. CONCLUSIONS: These advances will enable novel insight into the mechanisms of bladder control and pain as well as lay the groundwork for potential optogenetic and closed loop interventions to treat other visceral diseases. 
MP62-05 BLOCKADE OF CENTRAL ANGIOTENSIN II TYPE 1 RECEPTORS SUPPRESSES MICTURITION REFLEX IN RATS
Shogo Shimizu*, Takahiro Shimizu, Yoshiki Nagao, Kumiko Nakamura, Tamaki Kataoka, Shiho Kamada, Youichirou Hiagashi, Takaaki Aratake, Suo Zou, Tomoya Hamada, Yusuke Ueba, Masaki Yamamoto, Motoaki Saito, Nankoku, Japan INTRODUCTION AND OBJECTIVES: Psychological stress is involved in the development of the lower urinary tract symptoms. Our previous reports showed that centrally administered a stress-related neuropeptide, angiotensin II (Ang II) facilitates micturition reflex acting on the central Ang II type 1 (AT1) receptors. We investigated the possible mechanism which central Ang II facilitates micturition reflex focusing on the AT1 receptor downstream factor, corticotropinreleasing factor (CRF). Moreover, we examined whether a centrally acting AT1 receptor antagonist telmisartan suppresses the central Ang II induced micturition reflex.
METHODS: Male Wistar rats were anesthetized with urethane (1.0 g/kg, ip) in order to perform continuous cystometry. Vehicle, CRF type 1 receptor antagonist (CP154526: 3 or 10 nmol) or CRF type 2 receptor antagonist (K41498: 10 nmol) was icv administered 30 min before icv Ang II administration in the rats. Some rats were administered with telmisartan (1 or 10 mg/kg, po) or no centrally acting AT1 receptor antagonist valsartan (10 mg/kg, po) once daily for 8 days. Then, blood pressure was measured, and Ang II was icv administered in the rats.
RESULTS: Under the vehicle pretreatment, centrally administered Ang II significantly shortened intercontraction interval (ICI) compared to the vehicle administration. CP154526 but not K41498 significantly and dose-dependently suppressed Ang II-induced shortening of ICI compared to vehicle pretreatment. Chronic pretreatment with telmisartan or valsartan failed to affect the blood pressure. However, telmisartan (10 mg/kg) but not valsartan suppressed the Ang II-induced shortening of ICI.
CONCLUSIONS: The central Ang II facilitates micturition reflex via stimulation of central AT1 receptor/CRF1 receptor pathway. Peripherally administered AT1 receptor antagonist telmisartan suppresses the facilitated micturition reflex induced by central Ang II in rats.
